Scinai Immunotherapeutics to Discuss Potential Breakthrough Treatment for Rare Skin Disorders
Scinai Immunotherapeutics will host a webinar to explore the therapeutic potential of PC111, a novel monoclonal antibody targeting rare skin conditions like Pemphigus Vulgaris and SJS/TEN, following its recent acquisition of Pincell.
Scinai Immunotherapeutics will host a webinar to discuss the potential of PC111, a novel monoclonal antibody targeting rare skin disorders. The May 7 event, scheduled for 11:30 a.m. EST, will provide insights into the treatment's mechanism and development strategy for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).
The webinar follows Scinai's recent acquisition of Pincell and a related €12 million grant application under Poland's FENG program. Executives from both Scinai and Pincell will present, offering a comprehensive overview of the antibody's potential to address significant unmet medical needs in dermatological conditions.
PC111's unique approach targets soluble Fas ligand, which could represent a significant advancement in treating these rare and challenging skin disorders. By focusing on innovative immunology solutions, Scinai demonstrates its commitment to developing therapeutic products that address complex medical challenges.
The live Q&A segment will provide additional opportunity for stakeholders to understand the potential impact of this research, highlighting the ongoing efforts to develop targeted treatments for rare skin conditions that currently have limited therapeutic options.